Skip to content
DataLookout
Menu

NANO-GBMNCT04881032

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 1 month later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 2025 to Nov 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Secondary endpoints: details revised at 1 of 8 entries
    • Site details revised at 1 of 9 sites
    • Publications: details revised at 1 of 1 entry
  2. Notable Eligibility criteria expanded, about 11 words
    • Publications: details revised at 1 of 1 entry
    v7
  3. Notable Eligibility criteria revised
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 9 of 9 sites
    v6
  4. Notable Primary completion date: Sep 2024 to Sep 2025
    • Study sites: 6 to 9
    • Study completion date: Mar 2026 to Mar 2027
    • Publications: details revised at 1 of 1 entry
    v5
  5. Minor Site details revised at 2 of 6 sitesv4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Primary completion date: May 2024 to Sep 2024
    • Study completion date: Nov 2025 to Mar 2026
    • Start date changed from estimate of Dec 2021 to Mar 7, 2022
    v3
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date: May 2021 to Dec 2021
    • Primary completion date: Dec 2023 to May 2024
    • Study completion date: May 2025 to Nov 2025
    • Site details revised at 6 of 6 sites
    • Collaborator revised
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The recommended dose (phase I) of AGuIX in combination with TMZ and and radiotherapy during the radio-chemotherapy period
Timeframe: during 6 weeks after the first injection of AGuIX
6-month Progression Free Survival (PFS) rate (phase II)
Timeframe: 6 months from the start of treatment

Secondary (8)

Pharmacokinetic Cmax of AGuIX
Pharmacokinetic Tmax of AGuIX
Pharmacokinetic AUC of AGuIX
Pharmacokinetic t1/2 of AGuIX
distribution of AGuIX
Show 3 moreShow less
Overall Survival
Progression Free Survival (PFS)
Toxicity (CTCAE criteria)

Arms and interventions

AGuIX + chemoradiotherapy (radiotherapy + temozolomide)Experimental

addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II

chemoradiotherapy (radiotherapy + temozolomide)Sham comparator

standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II

Drugs: Polysiloxane Gd-Chelates based nanoparticles (AGuIX), Temozolomide

Radiation: radiotherapy

Sites

9 sites in 1 country